Treatment protocol for acute promyelocytic leukemia -FBMTG-APL2009
Not Applicable
- Conditions
- acute promyelocytic leukemia
- Registration Number
- JPRN-UMIN000001742
- Lead Sponsor
- Fukuoka Blood & Marrow Transplant Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1. The case having double cancers 2. The case with an infectious disease having difficulty with control 3. The case with a severe mental disorder 4. The pregnancy or breast-feeding woman 5. The case that the medical attendant judged to be inappropriate
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie FBMTG-APL2009 treatment for acute promyelocytic leukemia?
How does FBMTG-APL2009 compare to standard-of-care protocols like ATRA and arsenic trioxide in APL management?
What biomarkers are used to select patients for FBMTG-APL2009 therapy in acute promyelocytic leukemia?
What are the known adverse events associated with FBMTG-APL2009 and how are they managed in clinical practice?
Are there combination therapies or competitor drugs being evaluated alongside FBMTG-APL2009 for treating acute promyelocytic leukemia?